Kyowa Kirin Co ((KYKOF)) announced an update on their ongoing clinical study.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Kyowa Kirin Co. is conducting a clinical study titled ‘A Phase 1, Uncontrolled, Open-label, Non-randomized, Dose-escalation Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors.’ The study aims to determine the maximum tolerated dose (MTD) of KK2260, a new drug, while assessing its safety and efficacy in patients with advanced or metastatic solid tumors, including specific types like esophageal and head and neck squamous cell carcinoma.
The intervention being tested is KK2260, an experimental drug administered intravenously. The study will evaluate different dosing regimens to determine the most effective and safe approach for treating various cancer types.
This Phase 1 study is interventional, with a randomized allocation and parallel intervention model. It is open-label, meaning no masking is involved, and its primary purpose is treatment-focused.
The study began on September 26, 2023, and is currently recruiting participants. The primary completion and estimated study completion dates are yet to be confirmed, with the last update submitted on February 3, 2025.
The outcome of this study could significantly impact Kyowa Kirin Co.’s stock performance and investor sentiment, as successful results may position KK2260 as a promising treatment option in the oncology market. This could also influence competitors and the broader industry landscape.
The study is ongoing, with further details available on the ClinicalTrials portal.